Why the study?
Superior vena cava syndrome due to pacemaker leads is an uncommon complication with limited clinical trials on the use of direct oral anticoagulants for treatment.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
BACKGROUND: The use of cardiac implantable electronic devices has grown substantially over the past two decades, lead-related vascular issues are commonly encountered in clinical practice. Superior vena cava (SVC) syndrome due to pacemaker leads is an uncommon complication. Anticoagulation remains the mainstay of therapy to restore some degree of patency and relieve swelling. However, there are limited clinical trials on direct oral anticoagulants (DOACs). CASE PRESENTATION: We report a case of an 80-year-old man who developed SVC syndrome after transvenous pacemaker implantation with symptoms of obstruction that were significantly relieved after four months of DOACs. His symptoms had completely resolved nine months later. CONCLUSIONS: DOACs are effective in the treatment of SVC syndrome after pacemaker implantation, representing an important new approach. It is a very good choice for patients who do not want to undergo interventional therapy.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2023) conducted a case report in Pacemaker-induced superior vena cava syndrome (n=1). Rivaroxaban was evaluated on Symptom resolution.
Synapse has enriched 10 related papers. Consider them for comparative context: